Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.43 |
| ▸ | MAPKAPK5 | Q8IW41 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | STRADA | Q7RTN6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9110957 | 0.92 | MAPK14 (0.48) | MAPK14MAPKAPK2MAPKAPK5PTGER1 | |
| SCHEMBL9110549 | 0.92 | MAPKAPK2 (0.44) | MAPK14MAPKAPK2MAPKAPK5MAPK1PTGER1 | |
| SCHEMBL9111810 | 0.91 | MAPKAPK2 (0.42) | MAPK14MAPKAPK2MAPKAPK5MAPK1PTGER1 | |
| SCHEMBL9110834 | 0.91 | MAPK14 (0.44) | MAPK14MAPKAPK2MAPKAPK5MAPK1PTGER1 | |
| SCHEMBL9111751 | 0.91 | MAPKAPK2 (0.53) | MAPK14MAPKAPK2MAPKAPK5MAPK1 | |
| SCHEMBL9110416 | 0.88 | MAPK14 (0.55) | MAPK14MAPKAPK2MAPKAPK5ROCK2MAPK12 | |
| SCHEMBL9110271 | 0.87 | MAPK14 (0.48) | MAPK14 | |
| SCHEMBL9112057 | 0.87 | MAPKAPK2 (0.43) | MAPK14MAPKAPK2MAPKAPK5MAPK1ROCK2 | |
| SCHEMBL9109435 | 0.87 | MAPKAPK2 (0.58) | MAPK14MAPKAPK2MAPKAPK5MAPK1PTGER1 | |
| SCHEMBL9111092 | 0.86 | MAPKAPK2 (0.42) | MAPK14MAPKAPK2MAPKAPK5MAPK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3469907-B1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS INC (US) | 2021-03-03 | — | — | EP | claimed |
| EP-3469907-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | Aclaris Therapeutics, Inc. (US) | 2019-04-17 | — | — | EP | claimed |
| US-9365546-B2 | Substituted pyridinone-pyridinyl compounds | CONFLUENCE LIFE SCIENCES INC. (US) | 2016-06-14 | — | — | US | claimed |
| US-20140171449-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | CONFLUENCE LIFE SCIENCES INC. (US) | 2014-06-19 | — | — | US | claimed |
| US-20120142709-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2012-06-07 | — | — | US | claimed |
| EP-3469907-B1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS INC (US) | 2021-03-03 | — | — | EP | disclosed |
| EP-3469907-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | Aclaris Therapeutics, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-2648516-B1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS INC (US) | 2018-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142709-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | MAPK1, MAP3K1, MAP3K6 | MAPK14 47/4885MAPKAPK2 33/4885MAPKAPK5 35/4885 |
| US-20140171449-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | MAPK1, MAP3K1, MAP3K6 | MAPK14 47/4885MAPKAPK2 33/4885MAPKAPK5 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.